Table 3.
Univariable and multivariable analyses for major local recurrence
| Covariates | Univariable analysis | Multivariable analysis | ||||
|---|---|---|---|---|---|---|
| HR | CI | p-value | HR | CI | p-value | |
| Dose group | ||||||
| High-dose (reference) | 1.00 | – | – | 1.00 | – | – |
| Standard-dose | 2.50 | 0.77–8.17 | 0.13 | 4.00 | 1.13–14.17 | 0.031 |
| Age (years) | ||||||
| 40–64 (reference) | 1.00 | – | – | – | – | – |
| 65–74 | 0.77 | 0.22–2.74 | 0.69 | – | – | – |
| 75–86 | 0.85 | 0.21–3.41 | 0.82 | – | – | – |
| Sex | ||||||
| Female (reference) | 1.00 | – | – | – | – | – |
| Male | 0.98 | 0.22–4.43 | 0.98 | – | – | – |
| Tumor location | ||||||
| Mt (reference) | 1.00 | – | – | 1.00 | – | – |
| Ce or Ut | 3.00 | 0.75–12.04 | 0.12 | 4.24 | 0.91–19.80 | 0.066 |
| Lt | 1.97 | 0.53–7.35 | 0.31 | 2.86 | 0.70–11.59 | 0.14 |
| Tumor length (mm) | ||||||
| ≤ 40 (reference) | 1.00 | – | – | 1.00 | – | – |
| > 40 and ≤ 80 | 0.15 | 0.019–1.20 | 0.074 | 0.25 | 0.03–2.01 | 0.19 |
| > 80 | 1.11 | 0.30–4.09 | 0.88 | 4.5 | 0.93–21.91 | 0.062 |
| Clinical depth of invasion | ||||||
| EP/LPM or MM/SM1 (reference) | 1.00 | – | – | 1.00 | – | – |
| SM2 | 5.67 | 1.26–25.62 | 0.024 | 8.17 | 1.45–45.91 | 0.017 |
| Chemotherapy | ||||||
| Cisplatin + 5-fluorouracil (reference) | 1.00 | – | – | 1.00 | – | – |
| Others | 2.82 | 0.62–12.88 | 0.18 | 3.24 | 0.66–15.87 | 0.15 |
Abbreviations: HR Hazard ratio, CI Confidence interval, Mt Middle thoracic esophagus, Ce Cervical esophagus, Ut Upper thoracic esophagus, Lt Lower thoracic esophagus, EP/LPM Tumor limited to the epithelium or invading the lamina propria mucosa, MM/SM1 Tumor invading the muscularis mucosa or submucosa to a depth of ≤ 200 μm from the lower border of the muscularis mucosa, SM2 Tumor invading the submucosa to a depth of > 200 μm